PulseAugur
EN
LIVE 20:23:04
中文(ZH) 马应龙：子公司获得溴芬酸钠滴眼液药品注册证书

Ma Ying Long subsidiary gets drug registration for eye drops

By PulseAugur Editorial · [1 sources] ·

Ma Ying Long's subsidiary has received a drug registration certificate for Bromfenac Sodium Eye Drops from China's National Medical Products Administration. This medication is intended for the symptomatic treatment of inflammatory conditions affecting the outer and anterior parts of the eye, such as conjunctivitis and scleritis. In separate news, Korea Post is increasing its investment in high-yield assets like AI data centers and European real estate to offset losses in its traditional postal business. AI

RANK_REASON The cluster contains unrelated news items about a drug registration and investment strategies, lacking a cohesive central theme or significant event.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Ma Ying Long subsidiary gets drug registration for eye drops

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Meme
The cluster contains unrelated news items about a drug registration and investment strategies, lacking a cohesive central theme or significant event.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
127 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Mayinglong: Subsidiary Obtains Drug Registration Certificate for Bromfenac Sodium Eye Drops

    36氪获悉，马应龙公告，近日，公司子公司江西马应龙美康药业有限公司收到国家药品监督管理局核准签发的溴芬酸钠滴眼液《药品注册证书》。溴芬酸钠滴眼液用于外眼部和前眼部的炎症性疾病的对症治疗（结膜炎、巩膜炎、术后炎症）。

RELATED TOPICS